Literature DB >> 23339450

Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations.

Jamie Honeychurch1, Monique H M Melis, Simon J Dovedi, Lijun Mu, Timothy M Illidge.   

Abstract

The aim of this study was to assess the immunogenic potential of irradiated lymphoma cells in vivo and determine whether immunogenicity can be enhanced by modulation of the host immune system. Syngeneic murine lymphoma models irradiated ex vivo were used as an orthotopic cellular vaccination prior to challenge with viable tumor cells. We demonstrate that irradiated lymphoma cells are poorly immunogenic and that protective anti-tumor CD8 T-cell responses require the addition of immunostimulatory monoclonal antibody as an immune adjuvant, and increased frequency of antigen exposure by multiple vaccinations. Furthermore, we show the potential importance of macrophages in regulating immunogenicity of irradiated lymphoma cells and demonstrate that depletion of macrophages using clodronate-encapsulated liposomes considerably enhances primary vaccination efficacy in the presence of adjuvant anti-CD40 antibody. Our results demonstrate that the immunogenic potential of poorly immunogenic lymphoma cells dying after radiation therapy can be improved by modulation of the host immune system.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23339450     DOI: 10.3109/10428194.2013.769219

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

1.  Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.

Authors:  Timothy M Illidge; Jamie Honeychurch; Simon J Dovedi; Grazyna Lipowska-Bhalla; Stephen A Beers; Eleanor J Cheadle; Lijun Mu; Martin J Glennie
Journal:  Cancer Immunol Res       Date:  2016-05-30       Impact factor: 11.151

Review 2.  Development and Significance of Mouse Models in Lymphoma Research.

Authors:  Jordan N Noble; Anjali Mishra
Journal:  Curr Hematol Malig Rep       Date:  2019-04       Impact factor: 3.952

3.  Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo.

Authors:  Xuesong Wu; Brian C Schulte; Youwen Zhou; Dipica Haribhai; Alexander C Mackinnon; Jose A Plaza; Calvin B Williams; Sam T Hwang
Journal:  J Invest Dermatol       Date:  2014-04-29       Impact factor: 8.551

Review 4.  Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?

Authors:  Richard C Walshaw; Jamie Honeychurch; Tim M Illidge
Journal:  Br J Radiol       Date:  2016-09-14       Impact factor: 3.039

5.  CD40 therapy and surgery: a potential immunologic partnership.

Authors:  Katelyn T Byrne; Robert H Vonderheide
Journal:  J Immunother       Date:  2013-09       Impact factor: 4.456

6.  Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports.

Authors:  Chieh-Sheng Lu; Jin-Hwang Liu
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

Review 7.  Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.

Authors:  Franz Buchegger; Steven M Larson; Jean-Pierre Mach; Yves Chalandon; Pierre-Yves Dietrich; Anne Cairoli; John O Prior; Pedro Romero; Daniel E Speiser
Journal:  Clin Dev Immunol       Date:  2013-11-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.